AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in India. As per an agreement signed in late 2018, Abbott Healthcare had been promoting and distributing Dapagliflozin under the “Gledepa” brand name and the Dapagliflozin and Metformin combination under the […]
Novo Nordisk’s diabetes medication, Victoza (liraglutide), has gained U.S. Food and Drug Administration (FDA) approval for an expanded use, marking a significant step forward in the treatment of cardiovascular diseases among type 2 diabetes patients. This latest approval allows Victoza to be used to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular […]
Novo Nordisk diabetes drug Victoza (liraglutide) has been approved by the US FDA for treating major cardiovascular diseases associated with type 2 diabetes.
In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use its diabetes drug Victoza (liraglutide) for treating heart diseases associated with type 2 diabetes. This approval marks a pivotal expansion of Victoza’s usage, positioning it as a key player in […]